TYRP1 Antibody (TA99) - Chimeric - BSA Free

Flow Cytometry: TYRP1 Antibody (TA99) - Chimeric - BSA Free [NBP3-43531] -

Flow Cytometry: TYRP1 Antibody (TA99) - Chimeric - BSA Free [NBP3-43531] - Mouse splenocytes (A), B16F10 murine melanoma cells (B), KPC3 pacreas carcinoma cells (C) and KPC3 cells transfected with the TYRP1 gene (D) were fixed using 2% PFA, permeabilised using 0.5% Triton and were subject to a primary treatment of either buffer, mouse-IgG1 chimeric 2C11 or NBP3-43531 (TA99) (indicated above plots) before a secondary treatment with buffer, goat anti-mouse Ig-allophycocyanin (G-aM Ig-APC) or anti-HisTag-APC (aHis-APC) antibodies (indicated beside plots). In panel A, splenocytes were also stained with a commercially available anti-CD3 (2C11) antibody conjugated to phycoerythrin (PE); all cells (i-v) were CD3 and thus PE positive. In subpanel 'A v' an increase in APC fluorescence intensity (FI(APC)) indicates binding of aHis-APC to 2C11 bound to CD3 at the cell surface. Some Ig containing proteins expressed by the splenocytes may explain the increase in APC fluorescence in subpanel 'A iii'. In panel B an increase in FI(APC) in subpanel 'iii' indicates that TA99 binds to heavily expressed TYRP1 at B16F10 cell surfaces and is then detectable using an G-aM Ig-APC antibody. Conversely, G-aM Ig-APC did not detect 2C11 at the cell surface, whereas a subset of cells with 2C11 bound to the surface were detectable using aHis-APC. Panel C shows that TYRP1 is not detectable in KPC3 carcinoma cells ('Ci, iii, v') as expected, and that again, aHis-APC is able to detect a small subset of CD3 expressing cells ('C vi'). When transfected with the TYRP1 gene, KPC3 cells then strongly express TYRP1 and it becomes detectable ('D iii'). A small subset of CD3 positive cells was again detectable in TYRP1 transfected KPC3 cells ('D vi'). All analyses were made using FACSCanto flow-cytometer.